Loading...
Risk of de novo hepatocellular carcinoma following use of direct acting antiviral medications for treatment of chronic hepatitis C
Direct-acting antivirals (DAA) are now the mainstay of treatment for patients with chronic hepatitis C virus (HCV); however, there is some controversy over whether use of DAAs for HCV, as compared with interferon (IFN)-based regimens, leads to an increased risk of hepatocellular carcinoma (HCC) deve...
Na minha lista:
| Udgivet i: | Cancer Prev Res (Phila) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6893130/ https://ncbi.nlm.nih.gov/pubmed/31451519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-19-0162 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|